Clinical trials: insulin glargine
Type 2 Diabetes
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to…
- Trial name
- LixiLan-O (NCT02058147)
- Testing
- Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010)
- Where
- 273 sites in United States, Australia and 21 more
- Volunteers
- 1,170 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00184613
- Testing
- pump, insulin glargine, insulin aspart
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin…
- Trial name
- NCT05834868
- Testing
- THDB0206 Injection, Insulin Lispro Injection
- Where
- China
- Volunteers
- 1,040 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Healthy
A Study of LY3192767 in Healthy Participants
The main purpose of this study is to investigate the side effects related to LY3192767 when given as an injection under the skin to healthy participants.
- Trial name
- NCT03025009
- Testing
- LY3192767, Basal Insulin Peglispro, Insulin Glargine
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes
Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes
The investigators designed this prospective, randomized control study to compare the efficacy and safety between the basal insulin glargine therapy and metformin-based OADs after correction of the glucose toxicity with a short…
- Trial name
- NCT00978263
- Testing
- metformin-based Oral Antidiabetic Drugs, Glargine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Chongqing Medical University
Diabetes Mellitus, Type 1
A Study in Participants With Type I Diabetes Mellitus
The purpose of this study is: To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment. To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52…
- Trial name
- IMAGINE 3 (NCT01454284)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 1,114 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes
This is a phase 3, open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected pre-meal insulin in non-smoking patients with type 1 diabetes.
- Trial name
- NCT00127634
- Testing
- Human Insulin Inhalation Powder, Injectable Insulin, Insulin Glargine
- Where
- 61 sites in United States, Belgium and 4 more
- Volunteers
- 385 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing…
- Trial name
- BEGIN™ (NCT01068665)
- Testing
- insulin degludec, insulin glargine
- Where
- 116 sites in United States, Canada and 6 more
- Volunteers
- 460 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then…
- Trial name
- NCT03336528
- Testing
- Degludec, Glargine, Aspart
- Where
- 4 sites in United States
- Volunteers
- 180 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
The purpose of this study is to compare the change in glycemic control, as measured by hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin glulisine as mealtime insulin following a variable bolus…
- Trial name
- NCT00135057
- Testing
- insulin glulisine, insulin glargine
- Where
- United States
- Volunteers
- 281 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitis
Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients
The goal of this clinical trial is to demonstrate the non-inferior immunogenicity of GP40321 compared to Apidra® SoloStar® at a concentration of 100 U/mL in type 1 diabetes mellitus patients.
- Trial name
- NCT07070752
- Testing
- GP40321, Apidra® SoloStar®, RinGlar®
- Where
- 17 sites in Russia
- Volunteers
- 224 people
- Sponsor
- Geropharm
Diabetes Mellitus
Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis
Given the longer half life of insulin degludec compared to glargine /levemir ,investigators believe that insulin degludec will reduce the rate of recurrent DKA.
- Trial name
- NCT03001323
- Testing
- Degludec, Standard long-acting
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Hennepin Healthcare Research Institute
Diabetes
Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168)
The purpose of this study is to evaluate whether the within-subject variation in duration of action and time-action profile of glargine measured by isoglycemic clamp will be below prespecified levels.
- Trial name
- NCT01152242
- Testing
- Isoglycemic Clamp, Comparator: insulin glargine
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 2 diabetes mellitus (T2DM) also using insulin glargine.
- Trial name
- SORELLA2 (NCT02294474)
- Testing
- SAR342434, Humalog, insulin glargine HOE901
- Where
- 103 sites in United States, Argentina and 10 more
- Volunteers
- 505 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart…
- Trial name
- BOOST® (NCT01680341)
- Testing
- insulin degludec/insulin aspart
- Where
- 45 sites in United States, Algeria and 3 more
- Volunteers
- 272 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Basal Insulins - Pharmacodynamics
To purpose of this study is to compare the pharmacodynamic properties of insulin detemir, insulin glargine and NPH insulin after a single subcutaneous injection.
- Trial name
- NCT00566124
- Testing
- Insulin detemir, Insulin glargine, Insulatard
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Chronic Kidney Diseases
Outcome of Glargine Insulin in Renal Impairment Patients With Diabetic Ketoacidosis
The study aims to compare between the use of continuous low dose insulin infusion versus co-administration of low dose continuous insulin infusion and early subcutaneous insulin glargine in diabetic ketoacidosis patients with…
- Trial name
- NCT05219942
- Testing
- Glargine, normal saline
- Where
- Egypt
- Volunteers
- 52 people
- Sponsor
- Ain Shams University
Type 2 Diabetes, Endothelial Dysfunction
Endothelial Effects of Basal Insulin: Detemir Versus Glargine
Endothelial progenitor cell (EPC) level represents a surrogate marker of cardiovascular risk and an indicator of the ongoing vascular damage.
- Conditions
- Type 2 Diabetes, Endothelial Dysfunction, Cardiovascular Disease
- Trial name
- NCT00699686
- Testing
- Glargine, Detemir
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Padova
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
The purpose of this study is to assess the safety and efficacy of omarigliptin compared to placebo in participants with inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01755156
- Testing
- Omarigliptin, Glimepiride, Insulin glargine
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary Objective: To demonstrate the non-inferiority of insulin glargine 300 units per milliliter (U/ml) in comparison to insulin degludec 100 U/ml on glycemic control and variability in participants with diabetes mellitus.
- Trial name
- inRange (NCT04075513)
- Testing
- Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 343 people
- Sponsor
- Sanofi